Elucidation of the Hsp90 C-terminal inhibitor binding site.

The Hsp90 chaperone machine is required for the folding, activation, and/or stabilization of more than 50 proteins directly related to malignant progression. Hsp90 contains small molecule binding sites at both its N- and C-terminal domains; however, limited structural and biochemical data regarding the C-terminal binding site is available. In this report, the small molecule binding site in the Hsp90 C-terminal domain was revealed by protease fingerprinting and photoaffinity labeling utilizing LC-MS/MS. The identified site was characterized by generation of a homology model for hHsp90α using the SAXS open structure of HtpG and docking the bioactive conformation of NB into the generated model. The resulting model for the bioactive conformation of NB bound to Hsp90α is presented herein.

[1]  Giulio Rastelli,et al.  Exploring the Binding Site of C-Terminal Hsp90 Inhibitors , 2010, J. Chem. Inf. Model..

[2]  B. Blagg,et al.  Hsp90 inhibition: elimination of shock and stress. , 2010, Bioorganic & medicinal chemistry letters.

[3]  J. Buchner,et al.  Dynamics of heat shock protein 90 C-terminal dimerization is an important part of its conformational cycle , 2010, Proceedings of the National Academy of Sciences.

[4]  R. Scannevin,et al.  Corrections to Heat Shock Protein 90: Inhibitors in Clinical Trials , 2010 .

[5]  B. Blagg,et al.  KU135, a Novel Novobiocin-Derived C-Terminal Inhibitor of the 90-kDa Heat Shock Protein, Exerts Potent Antiproliferative Effects in Human Leukemic Cells , 2009, Molecular Pharmacology.

[6]  Johannes Buchner,et al.  Hsp90 is regulated by a switch point in the C‐terminal domain , 2009, EMBO reports.

[7]  D. Agard,et al.  Grp94, the endoplasmic reticulum Hsp90, has a similar solution conformation to cytosolic Hsp90 in the absence of nucleotide , 2009, Protein science : a publication of the Protein Society.

[8]  David A Agard,et al.  Species-dependent ensembles of conserved conformational states define the Hsp90 chaperone ATPase cycle. , 2008, Molecular cell.

[9]  B. Blagg,et al.  Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket. , 2008, Current medicinal chemistry.

[10]  R. Buey,et al.  Apo‐Hsp90 coexists in two open conformational states in solution , 2008, Biology of the cell.

[11]  J. Reinstein,et al.  Conserved Conformational Changes in the ATPase Cycle of Human Hsp90* , 2008, Journal of Biological Chemistry.

[12]  Robert P Hanzlik,et al.  Protein targets of reactive metabolites of thiobenzamide in rat liver in vivo. , 2008, Chemical research in toxicology.

[13]  Friedrich Förster,et al.  Multiple conformations of E. coli Hsp90 in solution: insights into the conformational dynamics of Hsp90. , 2008, Structure.

[14]  A. Ferrari,et al.  Structural Models and Binding Site Prediction of the C‐terminal Domain of Human Hsp90: A New Target for Anticancer Drugs , 2008, Chemical biology & drug design.

[15]  L. Pearl,et al.  The Hsp90 molecular chaperone: an open and shut case for treatment. , 2008, The Biochemical journal.

[16]  B. Blagg,et al.  Development of novobiocin analogues that manifest anti-proliferative activity against several cancer cell lines. , 2008, The Journal of organic chemistry.

[17]  Rodrigo Lopez,et al.  Clustal W and Clustal X version 2.0 , 2007, Bioinform..

[18]  B. Blagg,et al.  Hsp90: a novel target for the disruption of multiple signaling cascades. , 2007, Current cancer drug targets.

[19]  B. Blagg,et al.  High-throughput assay for the identification of Hsp90 inhibitors based on Hsp90-dependent refolding of firefly luciferase. , 2007, Bioorganic & medicinal chemistry.

[20]  B. Blagg,et al.  Synthesis and evaluation of coumermycin A1 analogues that inhibit the Hsp90 protein folding machinery. , 2006, Organic letters.

[21]  L. Pearl,et al.  Structure and mechanism of the Hsp90 molecular chaperone machinery. , 2006, Annual review of biochemistry.

[22]  Paul Workman,et al.  Inhibitors of the HSP90 molecular chaperone: attacking the master regulator in cancer. , 2006, Current topics in medicinal chemistry.

[23]  L. Pearl,et al.  Crystal structure of an Hsp90–nucleotide–p23/Sba1 closed chaperone complex , 2006, Nature.

[24]  D. Mok,et al.  Modulation of Chaperone Function and Cochaperone Interaction by Novobiocin in the C-terminal Domain of Hsp90 , 2006, Journal of Biological Chemistry.

[25]  Laxmikant V. Kalé,et al.  Scalable molecular dynamics with NAMD , 2005, J. Comput. Chem..

[26]  Xiao Ming Yu,et al.  Hsp90 inhibitors identified from a library of novobiocin analogues. , 2005, Journal of the American Chemical Society.

[27]  Xiao Ming Yu,et al.  Syntheses of photolabile novobiocin analogues. , 2004, Bioorganic & medicinal chemistry letters.

[28]  R. Matts,et al.  Novobiocin induces a distinct conformation of Hsp90 and alters Hsp90-cochaperone-client interactions. , 2004, Biochemistry.

[29]  P. Charifson,et al.  Crystal Structures of Escherichia coli Topoisomerase IV ParE Subunit (24 and 43 Kilodaltons): a Single Residue Dictates Differences in Novobiocin Potency against Topoisomerase IV and DNA Gyrase , 2004, Antimicrobial Agents and Chemotherapy.

[30]  L. Neckers,et al.  The Heat Shock Protein 90 Antagonist Novobiocin Interacts with a Previously Unrecognized ATP-binding Domain in the Carboxyl Terminus of the Chaperone* , 2000, The Journal of Biological Chemistry.

[31]  L. Neckers,et al.  Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins. , 2000, Journal of the National Cancer Institute.

[32]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[33]  V. Thulasiraman,et al.  Molybdate inhibits hsp90, induces structural changes in its C-terminal domain, and alters its interactions with substrates. , 1999, Biochemistry.

[34]  L. Pearl,et al.  Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. , 1999, Journal of medicinal chemistry.

[35]  Walter H.J. Ward,et al.  The entropic penalty of ordered water accounts for weaker binding of the antibiotic novobiocin to a resistant mutant of DNA gyrase: a thermodynamic and crystallographic study. , 1997, Biochemistry.

[36]  Neal Rosen,et al.  Crystal Structure of an Hsp90–Geldanamycin Complex: Targeting of a Protein Chaperone by an Antitumor Agent , 1997, Cell.

[37]  T. Blundell,et al.  Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.

[38]  P. Thibault,et al.  Fragmentation reactions of multiply-protonated peptides and implications for sequencing by tandem mass spectrometry with low-energy collision-induced dissociation. , 1993, Analytical chemistry.

[39]  E. Myers,et al.  Basic local alignment search tool. , 1990, Journal of molecular biology.

[40]  B. Blagg,et al.  Characterization of a novel novobiocin analogue as a putative C‐terminal inhibitor of heat shock protein 90 in prostate cancer cells , 2010, The Prostate.